Trials / Withdrawn
WithdrawnNCT01738841
Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Post-marketing Surveillance Study of GSK Biologicals' Live, Attenuated Measles, Mumps, Rubella and Varicella Vaccine, Priorix-Tetra, Following a Single Vaccine Dose Given According to Local Prescribing Information in the Philippines
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 12 Years
- Healthy volunteers
- Accepted
Summary
This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.
Detailed description
The participating physicians will enroll only those subjects for whom they would prescribe Priorix-Tetra in the course of their normal clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Priorix-Tetra™ | Single dose, subcutaneous injection |
| OTHER | Safety data collection | Recording of adverse events, using diary cards |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2012-11-30
- Last updated
- 2013-07-22
Source: ClinicalTrials.gov record NCT01738841. Inclusion in this directory is not an endorsement.